Our products

Developing tumor classification tests is the common thread of Genexpath's activity. These products have been implemented to respond as closely as possible to the needs of professionals who contribute to the diagnosis and treatment of patients.

Classification tests

Genexpath currently markets 2 tumor classification tests: LymphoSign test and SarcomaFusion test. These tests combine a test in Vitro test (RT-MLPA) and bioinformatics analysis after NGS sequencing.
Our products are optimized for difficult samples or small quantities. The simple and fast protocol facilitates the deployment of the technique within the various departments. It does not require any specific hardware. Conventional laboratory equipment is sufficient as well as an NGS sequencer.

These tests can be sequenced simultaneously with other libraries and require only 100,000 reads per sample. This is a big advantage for laboratories and a significant cost reduction. It is not necessary to wait to have enough samples to start sequencing nor to monopolize the sequencer for these tests only.

After sequencing, our RT-MIS software, combined with artificial intelligence for the classification of non-Hodgkin lymphomas, facilitates the interpretation of the results.
The use of RT-MIS is simple and fast, without local installation. The results provided are extremely complete.

These tests are the result of research work carried out in inserm unit 1245 at Henri Becquerel Center of Rouen with whom Genexpath collaborates closely. They are now available to all hospitals, worldwide.

GenerateReports software

Genexpath also markets the software GenerateReports which allows the analysis and interpretation of high-throughput sequencing results.
GenerateReports supports a wide variety of raw data and incorporates the latest algorithms published in the literature for variant detection.
GenerateReport is economical and adapts perfectly to the multicentric research projects that we are very proud to be able to support.

In the future, Genexpath aims to develop and/or industrialize other classification tests in order to facilitate the work of professionals. Our ambition is also to once again make the work of researchers available to as many people as possible.